J. Goldman & Co’s Alnylam Pharmaceuticals ALNY Stock Holding History

J. Goldman & Co’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.65M	Sell	8,000 -13,500	-63%	-$4.59M	0.08%	276
2025 Q4	$8.55M	Buy	+21,500	New	+$9.52M	0.23%	123
2025 Q2	–	Sell	-36,000	Closed	-$9.72M	–	451
2025 Q1	$9.72M	Buy	+36,000	New	+$9.25M	0.24%	132
2023 Q1	–	Sell	-6,800	Closed	-$1.62M	–	352
2022 Q4	$1.62M	Buy	+6,800	New	+$1.45M	0.08%	191
2018 Q2	–	Sell	-26,500	Closed	-$3.16M	–	350
2018 Q1	$3.16M	Buy	+26,500	New	+$3.42M	0.13%	172

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

J. Goldman & Co's ALNY Position: Q1 2026 in Review

J. Goldman & Co sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 3,368 shares — an estimated $1.15M sold.

J. Goldman & Co first reported a position in ALNY in Q1 2025 and held it in 2 quarters. The position peaked at $20M in Q1 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

J. Goldman & Co reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
J. Goldman & Co sold 3,368 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $1.15M.
J. Goldman & Co first reported a position in Alnylam Pharmaceuticals in Q1 2025 and held it in 2 quarters.
J. Goldman & Co's Alnylam Pharmaceuticals position peaked at $20M in Q1 2025.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.